PDCD1 and neoplasm: By analyzing 373 IMLI patients treated with PD-1/PD-L1 inhibitors across different tumor types, we revealed a bimodal onset, uniform injury patterns and severity across tumor types, and NK cells as a potential predictive marker, which helps to optimize advancing personalized monitoring and universal therapeutic decision-making.